There aren't many all comer trials because not many companies are developing drugs that work in all cancer types these days. Even Keytruda is tied to PD-1 expression as a biomarker.
RAC really is an unusual company with a very unusual drug. You really need to build your valuation bottom up from first principles. Imagine what doxorubicin would be worth if it had only been discovered a couple of years ago and had more than 15 years of patent protection left.
Intellectual Property (IP) Waterproofing., page-40
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
